Adam Gehring

Title: Adam Gehring: Innovator in Hepatitis B Research

Introduction

Adam Gehring is a notable inventor based in Singapore, SG. He has made significant contributions to the field of medical research, particularly in the treatment of Hepatitis B Virus (HBV) and Hepatocellular Carcinoma (HCC). With a total of 2 patents, Gehring's work focuses on innovative solutions that address critical health challenges.

Latest Patents

Gehring's latest patents include the development of an HBV epitope reactive exogenous T cell receptor (TCR) and its applications. This invention provides at least one isolated cell comprising an HBV epitope-reactive exogenous T cell receptor and methods for producing them. The patent outlines the use of polynucleotides, constructs, and vectors encoding the T cell receptor for therapeutic purposes in treating HBV and HCC. Additionally, it includes kits and methods for the detection of HBV and HCC. Another significant patent involves a T-cell that recognizes the epitope HBC18-27 of the hepatitis B viral core antigen, further enhancing the potential for targeted treatments.

Career Highlights

Adam Gehring is affiliated with the Agency for Science, Technology and Research, where he continues to advance his research and innovations. His work is pivotal in the ongoing battle against viral infections and cancer, showcasing his commitment to improving public health outcomes.

Collaborations

Gehring collaborates with esteemed colleagues in his field, including Antonio Bertoletti, to enhance the impact of his research and innovations.

Conclusion

Adam Gehring's contributions to the field of medical research, particularly in the treatment of Hepatitis B and related conditions, highlight his role as a leading inventor. His innovative patents and ongoing work continue to pave the way for advancements in healthcare.